Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2005 Dec;19(6):1137-45, viii.

Antiangiogenic therapies for mesothelioma.

Author information

  • 1University of Texas-Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8852, USA. jonathan.dowell@utsouthwestern.edu

Abstract

A large body of preclinical evidence suggests that angiogenesis plays a key role in the pathogenesis of malignant mesothelioma. Several mediators of angiogenesis seem to be autocrine growth factors in mesothelioma, and in preclinical models, agents that target angiogenesis produce tumor regression. Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions.

PMID:
16325128
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk